Once-Daily pill may protect blood vessels better in black kidney transplant patients

NCT ID NCT03841097

Ongoing Disease control Sponsor: Roy D. Bloom, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at two versions of the drug tacrolimus, which is used to prevent organ rejection after a kidney transplant. One version is taken once a day, the other twice a day. The goal is to see which one does a better job at keeping blood vessels healthy, measured by how stiff they are. The study involves 60 African American kidney transplant recipients and will follow them for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tacrolimus (extended-release and immediate-release forms)
What this could lead to: If successful, this could show that a once-daily version of tacrolimus is better for heart and blood vessel health than the twice-daily version in African American kidney transplant patients.
What could go wrong: This is a small, single-center study with only 60 participants, so results may not apply to all patients. The study is also observational in nature and does not test a new drug, so any benefits are about choosing between existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT; COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT; COMPLICATIONS

Contacts and locations

Locations

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.